Clinithink secures growth-equity investment from TT Capital Partners and MSD Global Health Innovation Fund
Leading healthcare technology investors join the round to support global expansion and service development.
Clinithink provides clinical data insights to healthcare and life sciences organisations through its patented natural language processing platform. The company extracts structured intelligence from unstructured medical records to inform treatment decisions, trial recruitment, and reimbursement.
Clinithink has secured growth-equity backing from TT Capital Partners and the MSD Global Health Innovation Fund to support its international expansion and service development.
The company applies artificial intelligence to parse large volumes of unstructured medical documents rapidly, helping healthcare providers and life sciences firms with precision medicine, patient matching, and revenue cycle management.
The latest capital injection will enable the firm to scale its operations globally and widen its commercial offering.
From the founder
"We are delighted to have been able to close this latest round of funding with TTCP and MSD GHI. Not only because it enables us to expedite our growth but, strategically, we now have two further partners whose business is all about innovation."
Chris Tackaberry
CEO at Clinithink
Investor perspective
"We look forward to collaborating with Clinithink’s world-class team as they continue to improve the lives of patients around the world."
Conor Green
Partner, TT Capital Partners
Use of funds
- 01Expand into international markets
Investors
Categories
About the company
Clinithink
Clinithink offers a natural language processing platform that transforms unstructured medical data into clinical insights.